Key Takeaway: The active ingredient in both treatments is semaglutide, which mimics the GLP-1 hormone to reduce appetite
Low concentration: 0.1% to 0.5% Entry-level copper peptide products typically contain 0.1% to 0.5% GHK-Cu
The GLP-1 Agonist Boom in ME/CFS, FM and Long COVID: Insights, Using it, Trials Underway by Cort Johnson | Nov 3, 2025 | COVID-19, Dempsey, Epstein-Barr Virus, GLP-1, Gut, Homepage, Immune, Inflammation, Kaufman, Mast cell activation syndrome, Mast cell activation syndrome, Neuroinflammation, Pathogens, POTS, RECOVER Initiative, Severe ME/CFS, Treatment Complex, chronic illness experts discuss what GLP-1 agonists can and can't do in diseases like ME/CFS, long COVID, and POTS
Es untersttzt die Herzfunktion, indem es den Herzmuskel mit Energie versorgt und vor oxidativem Stress schtzt
GLP-1 acts as a satiety hormone [21], transmitting signals of fullness from the gut to the brain and activating GLP-1R mediated by paracrine activations of vagus afferent neurons innervating the gastrointestinal tract [22, 23]
